🟢 CalciMedica is trading 11.1% up today after FDA alignment on Phase 2b trial design for Auxora

CalciMedica is trading 11.1% up today at $0.83 after the FDA aligned with the company on the Phase 2b trial design for its Auxora therapy in acute pancreatitis.

• The clinical trial will utilize a primary endpoint of new-onset severe respiratory failure, providing a clear regulatory path forward for the treatment.
• Market participants view the regulatory clarity as a major de-risking milestone for the company's lead clinical program.
• The current price action extends a multi-day rebound following recent volatility, aided by a broadly positive market backdrop.